US20070149876A1 - Methods and devices for non-invasively measuring quantitative information of substances in living organisms - Google Patents

Methods and devices for non-invasively measuring quantitative information of substances in living organisms Download PDF

Info

Publication number
US20070149876A1
US20070149876A1 US11/680,927 US68092707A US2007149876A1 US 20070149876 A1 US20070149876 A1 US 20070149876A1 US 68092707 A US68092707 A US 68092707A US 2007149876 A1 US2007149876 A1 US 2007149876A1
Authority
US
United States
Prior art keywords
electrodes
processor
impedance
substance
signals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/680,927
Inventor
Vahram Mouradian
Valeri Armenakyan
Maksim Malkin
Gagik Farmanyan
Minas Hambardzumyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calisto Medical Inc
Original Assignee
Calisto Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calisto Medical Inc filed Critical Calisto Medical Inc
Priority to US11/680,927 priority Critical patent/US20070149876A1/en
Assigned to CALISTO MEDICAL, INC. reassignment CALISTO MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARMENAKYAN, VALERI, FARMANYAN, GAGIK, HAMBARDZUMYAN, MINAS, MALKIN, MAKSIM, MOURADIAN, VAHRAM
Publication of US20070149876A1 publication Critical patent/US20070149876A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053Measuring electrical impedance or conductance of a portion of the body
    • A61B5/0537Measuring body composition by impedance, e.g. tissue hydration or fat content

Definitions

  • the invention relates in general to medical measuring devices and in particular to methods and devices for non-invasively measuring quantitative information of substances in living organisms.
  • the living organism and its functioning systems are sources of extremely weak electromagnetic oscillations in a broad spectrum of frequencies.
  • Several holistic therapeutic processes take advantage of such principles. These therapeutic processes utilize specific ultra fine oscillation information and are generally known as “bioresonance therapy.”
  • BRT bioresonance therapy
  • Dr. F. Morrell who presented the use of his idea for the first time in 1977.
  • Dr. Morrell's postulated that all disease and their pre-conditions are accompanied or caused by electromagnetic oscillations. According to Dr. Morrell's postulations, there is no pathological phenomenon without the presence of pathological oscillations in or around the body.
  • Pathological electromagnetic oscillations are active alongside the healthy oscillations in the body of every patient. Because the patent's own oscillations or signals are electromagnetic in nature, they can be detected by using electrodes and electromagnetic measurement devices. Using what is known as a separator, the harmonious oscillations, which are virtually identical in all humans, may be filtered out through a filter. Interfering frequencies, which may be caused by pathogens, are not captured by the filter. Thus, the separator only resonates with harmonious frequencies. In this way, it is possible to separate harmonious and disharmonious frequencies.
  • Diabetes is a life threatening disease which affects an estimated 20 million Americans, out of whom 50% are not aware of having it. The latest statistical estimates indicate there are approximately 125 million people diagnosed with diabetes worldwide, and that number is expected to rise 220+million by the year 2010. Early detection of diabetes is manageable allowing those affected to live longer and healthier lives. Blood glucose level monitoring and tracking provides valuable information to help control patients with diabetes. Diabetic people who using insulin regularly need to check the glucose level three or more times per day. This process of monitoring the glucose level allows doctors to have prompt and primary information in detecting the cure for disease.
  • a method and system for non-invasively measuring a level of a substance level in a living organism, the method comprises: measuring the electrical potential between points on different meridians of vegetative system, or between different points on the skin of the organism; storing the measured value as reference point; applying a plurality of low current electrical signals, where each signal corresponds to a previously extracted electrical signal derived from a known concentration of the substance to determine a maximum difference between the reference point and the responses to the electrical signals, then determining the amount of the substance in the living organism by using the maximum difference and previously determined table to correlate the amount of the substance with the maximum difference.
  • a method of determining a substance in a living organism comprising: applying an electrical signature signal to the living organism, wherein the electrical signature signal corresponds to a predetermined amount of the substance; measuring the response of the living organism to the applied signature signal; and determining whether an elevated response has resulted from applying the electrical signature, if so, then determining the amount of the substance in the living organism from the predetermined amount of the substance.
  • the detection of the “body response” is based on the monitoring of the level of convergence of sequentially generated curves of conductivity change versus time for the same substance signature wave applied to the body between two points on the skin.
  • One aspect uses an internal database of self-oscillation frequencies extracted from hundreds of biological solutions with different levels of glucose, covering the range of blood glucose levels from 10 mg/dl to 600 mg/dl.
  • a low-current electrical signal for every entry in the reference database may be applied to a patient at predetermined points on the skin or acupuncture points. These electrical signals are applied at points where the electrical potential has been previously measured to establish a calibration aculevel. Then the measured aculevel for every data point is compared with the calibration aculevel. A large disturbance/change between these values suggests the blood glucose level in the patient.
  • an apparatus for measuring a substance in a living organism may comprise: a processor means; at least two electrode means for applying and receiving signals, an impedance measuring means for determining the impedance between the at least two electrode means; a memory means for storing a database of electrical signature signals, wherein each electrical signature signal corresponds to different amounts of a substance; and a means for applying the electrical signature signals to the at least two electrode means.
  • FIG. 1 a is a schematic diagram illustrating one embodiment of the present invention.
  • FIG. 1 b is a schematic diagram illustrating an impedance meter which could be used in various embodiments of the present invention.
  • FIG. 1 c is a schematic diagram illustrating a reset circuit which could be used in various embodiments of the present invention.
  • FIG. 2 illustrates a general process for non-invasively measuring quantitative information of substances in living organisms.
  • FIG. 3 a illustrates a detailed process for non-invasively measuring quantitative information of substances in living organisms.
  • FIG. 3 b is a continuation of the process illustrated in FIG. 3 a.
  • FIGS. 4 a - 4 b illustrate graphs of curves which illustrate impedance measurements occurring in the time domain.
  • FIG. 5 is a schematic diagram illustrating another embodiment of the present invention.
  • FIG. 6 a is a perspective view illustrating a portable device incorporating one or more aspects of the present invention.
  • FIG. 6 b is an exploded perspective view of the portable device illustrated in FIG. 6 a.
  • Acupuncture points are well known in Chinese medicine. In the 1950's, Dr. Reinhard Voll studied acupuncture and learned that the body has about 2000 points on the skin which follow twenty lines called meridians. According to Chinese traditional medicine, meridians are channels of energy and that energy movement is called Qi. Western studies have also shown that acupuncture points may be found by mapping skin electrical resistances. Thus, acupuncture points are specific superficial anatomic locations where the skin on or over these points is lower in electrical resistance than the surround skin, making acupuncture points strategic conductors of electromagnetic signals in the body. Some studies have shown that acupuncture point resistance is approximately half that of the surrounding skin (or conductance is twice as higher).
  • disharmonious frequencies e.g., the signature frequency of certain pathogens
  • these inverted frequencies as well as harmonious oscillations from the separator may be fed back to the patient using an electrode.
  • the patient's own electromagnetic field reacts to the therapy signals and in turn enters a modified pattern into the measurement devices and separator. This process may be repeated and thus the pathological signals in the body are consequently reduced and finally extinguished. It has been shown that eliminating the pathological signals from the body has a beneficial therapeutic effect.
  • One aspect of the present invention recognizes that certain substances, such as glucose also have a particular electromagnetic oscillation or frequency.
  • a “substance” is matter of a particular or definite chemical composition, such as glucose.
  • the oscillations associated with a particular substance may change as the amount of the substance changes within an organism.
  • various aspects of the present invention use electromagnetic oscillations to determine the substance concentration, such a blood glucose, within a living organism.
  • every substance also has its own magnetic “self” frequency oscillation.
  • the frequency of a reagent When the frequency of a reagent is introduced into the organism through an electrode, the frequency of the reagent interacts with the frequency of the organism and creates a change in amplitude of the frequency. The response or change in amplitude or “excitation” of the signal can be detected and measured.
  • the reference point can be also a first conductance/resistance measurement applying the same reagent signature.
  • the frequency that produces the greatest excitation is the frequency that corresponds to the level of the substance in the organism.
  • a low-current electrical signal having a particular frequency may be introduced into the organism, which is applied at acupressure points or any other points on the human body where the electrical potential has been previously measured. This process may be repeated for every correlation in the reference database until a match (e.g. the signal that produces the greatest excitation) is found.
  • the measuring device 10 for measuring the levels of a substance in a living organism.
  • the measuring device 10 comprises a user interface 12 .
  • the user interface 12 may comprise one or more interfaces which are capable of receiving input and presenting output to a user or software agent. Specific aspects of the user interface 12 may include a display, a touch sensitive input screen, input keys, microphones and/or speakers (not shown).
  • the user interface 12 may be in communication with a processor 14 .
  • the processor 14 controls the processes and various functions of the measuring device 10 .
  • the processor 14 may be coupled to a first memory 16 .
  • the memory 16 may be built into the processor 14 or be an external memory chip.
  • the processor 14 may also be in communication with a second memory 18 .
  • the second memory 18 may be an external memory chip or memory built into the processor 14 .
  • the second memory may contain a reference database 20 , such as a database of extracted glucose reagent signatures.
  • the reference database 20 may be a table of values correlating reference or signature frequencies to specific levels of a substance in a “reagent.”
  • a reagent is a substance typically mixed with a liquid or solvent to form a compound.
  • the reagent may be selected because of its biological or chemical activity.
  • the reagent may be used to determine the self oscillating frequency of a substance.
  • a table of correlating the self oscillating frequencies to amounts of a substance in a reagent may be built and loaded into the database 20 .
  • the memory 18 may be in communication with a pair of electrodes 22 a and 22 b .
  • one electrode may be active-positive and the other electrode may be passive-negative.
  • the electrodes 22 a and 22 b are adapted to interact with the skin of the organism and may be used to measure the impedance between two points on the skin.
  • the electrodes are in communication with an impedance meter 24 which determines or measures the impedance between the electrodes 22 a and 22 b .
  • the impedance meter 24 may be in communication with an amplifier 26 , which amplifies signals sent from the impedance meter 24 .
  • the amplifier 26 may in communication with an analog-to-digital converter 28 which converts analog signals from the amplifier to the digital signals.
  • the digital signals may be sent to the processor 14 .
  • a reset circuit 30 may also be coupled to the measuring device 10 and in communication with the processor 14 .
  • the reset circuit 30 may also in communication with the electrodes 22 a and 22 b .
  • the reset circuit 30 may be adapted to clear or “short out” any residual charge between the electrodes. In other words, the reset circuit 30 clears any residual capacitance and/or changes polarization which may have developed on the skin between the electrodes.
  • the measuring device 10 may be powered by a power source, such as a battery (not shown).
  • a circuit 39 determines the relative change of impedance between two electrodes outputs a corresponding voltage which represents the change in impedance.
  • the circuit 39 may comprise leads 40 a and 40 b to the electrodes 22 a and 22 b ( FIG. 1 ), respectively.
  • the lead 40 a may be coupled to the negative or inverting input of an operational amplifier 42 .
  • the positive or non-inverting input of the operational amplifier 42 may be coupled to a partial circuit comprising a resister 44 , a common ground 46 , a voltage reference 48 , and a resistor 50 .
  • the positive lead of the voltage reference 48 and the negative lead of the resistor 50 may be coupled to a resistor 52 .
  • the resistor 52 may be coupled to the lead 40 a and the negative input of the operational amplifier 42 .
  • the lead 40 b is coupled to the output of the operational amplifier 42 .
  • a resistor 54 also couples the leads 40 a to the lead 40 b .
  • the output of the operational amplifier 42 sends a voltage to a variable gain amplifier 56 , which is also adapted to receive signals from the processor 14 ( FIG. 1 ).
  • the circuit 39 sends a voltage to the variable gain amplifier 56 which corresponds to the change in impedance between the electrodes.
  • the variable gain amplifier 56 amplifies the voltage and sends the amplified signal to an analog-to-digital converter 58 .
  • the analog-to-digital converter 58 converts the analog signals from the variable gain amplifier 56 and sends the converted digital signals to the processor 14 .
  • FIG. 1 c there is illustrated one aspect of the reset circuit 30 .
  • a generic analog switch 60 adapted to receive input commands from the processor 14 ( FIG. 1 ) from a lead 62 .
  • the analog switch 60 may also be in communication with the electrodes 22 a and 22 b ( FIG. 1 ) through the leads 64 a and 64 b , respectively.
  • the analog switch 60 Upon receiving the appropriate command from the processor 14 , the analog switch 60 is thrown, which effectively “shorts” out any residual charge between the electrodes.
  • the circuit may be adapted to alternate the polarity of the electrodes 22 a and 22 b.
  • FIG. 2 illustrates a general method 200 to determine the amount of a particular substance in an organism, such as a human body.
  • the process starts at step 202 and proceeds to step 204 where an electrical signature wave or signal corresponding to one frequency is applied to the electrodes (e.g., electrodes 22 a and 22 b of FIG. 1 ) which may be in contact with the skin of the organism.
  • the applied electrical signature signal correlates to a predetermined concentration of the substance.
  • there is a pre-existing reference database e.g., database 20 of FIG. 1
  • a conventional memory chip containing correlations between “signature” signal frequencies (e.g., 22-44 kilohertz) and known concentrations of a substance reagent.
  • each signature frequency in the database correlates to a known concentration of a substance in an organism.
  • step 206 a response or “excitation” to the applied signature signal is measured.
  • step 208 the process determines whether the response is “elevated.” In other words, did the organism respond in such a way as to indicate a positive correlation between applied electrical signal and the known concentration of the substance. If it is determined that the response to the applied electrical signature is elevated, then the process flows to step 210 where a correlation may be made between to determine the level of the substance (such as glucose) in the organism. On the other hand, if there is not an elevated response, the process may flow back to step 204 , where, in some embodiments, a new electrical signature wave may be applied.
  • the process may iteratively apply a plurality of electrical signature signals, where each signal corresponds to a particular concentration of a substance.
  • the electrical signature signal (or signals) that caused the greatest amount of excitation may be determined and the reference database may be again accessed to determine the particular level of the substance that corresponds with the frequency.
  • the level of the substance can, therefore, be determined and displayed through a user interface.
  • the self-oscillation frequencies of different concentrations of glucose molecules in the human blood can be matched with similar frequencies of pre-known concentrations of glucose in reference solutions. Once a frequency is matched, the corresponding glucose level in the blood can be readily determined.
  • FIGS. 3 a and 3 b illustrate a detailed exemplary embodiment of the general method illustrated in FIG. 2 .
  • the process starts in step 302 .
  • a signal from the user interface initiates the process.
  • the process may be initiated by the processor as a result of a preprogrammed schedule or timer circuit.
  • the process then proceeds to step 304 where the electrical impedance between two different points on the skin is measured via the electrodes 22 a and 22 b .
  • the two points may be acupuncture points which lie on different meridians.
  • the process determines whether the impedance signal (e.g., the voltage representing the impedance) is within acceptable predetermined limits.
  • the amplifier gain may be adjusted. If the readings are not within the predetermined limits, in step 308 , a gain factor is calculated. In step 310 , the gain factor may be stored in memory for later use in making additional impedance measurements. In step 312 , the gain factor may be used to adjust the gain of the amplifier. The process then flows back to step 304 where the impedance is again measured. At step 306 , the process determines whether the new impedance signal is within acceptable predetermined limits. Once it has been determined the signal is within acceptable limits, process flows to step 314 .
  • a first signature signal from the reference database 20 is applied on the electrodes.
  • the signature wave corresponds to a known level of glucose.
  • a series of measurements of the electrical impedance is then performed in the time domain which creates a first data set.
  • the first data set may be represented by a curve 402 on the graph illustrated in FIG. 4a .
  • the vertical axis represents the response or measured impedance.
  • the horizontal axis represents time.
  • each point on the curve represents the measured value of impedance at a particular time from the occurrence of the application of the signature signal.
  • step 318 the residual voltage on the electrodes may then be cleared as discussed in reference to FIG. 1 c .
  • step 320 the signature signal is again applied through the electrodes. This is the same signal which was applied in step 314 .
  • step 322 another series of measures of the electrical impedance is performed in the time domain which creates a second data set.
  • the second data set may be represented by curve 404 of the graph illustrated in FIG. 4 b .
  • the steps 314 through 322 may be repeated to produce additional data sets if predefined indicators, such as quality-of-measurement indicators, are not met.
  • step 324 the data sets are compared to each other to determine whether convergence has been achieved.
  • the amount of convergence may be graphically represented by the graph illustrated in FIG. 4c which shows curve 402 superimposed onto curve 404 . If convergence has not been achieved, the process flows directly to step 328 . If convergence has been achieved, then in step 326 , the process stores the signature sets as a candidate data set before it flows to step 328 .
  • step 328 the process determines whether all of the signature signals in the database have been applied. If not, the process flows to step 330 ( FIG. 3a ), where the residual voltage is removed as discussed in reference to FIG. 1 c . From step 330 , the process flows to step 332 , where the next signature signal in the database is set up to be applied to the electrodes. The process then flows back to step 314 , where the steps 314 through 328 are repeated for the new signature signal. On the other hand, if in step 328 , it is determined that all of the signature signals have been applied to the electrodes, the process flows to step 334 .
  • step 334 the logic reviews the stored candidate data sets to determine the set having the maximum convergence or the “best” candidate out of the stored candidate data sets. Using the frequency responsible for producing the best candidate, in step 336 , the reference database may then be accessed to determine the level of the substance that corresponds with the signal. The level of the substance can, therefore, be determined and sent to a user interface. The process ends at step 338 .
  • the measuring device 500 comprises a pair of electrodes 502 a and 502 b .
  • One electrode is active-positive and the other electrode is passive-negative.
  • the electrodes 502 a and 502 b are adapted to interact with the skin of the organism and may measure the electro conductivity between two points on the skin, such as two points on different meridians.
  • the electrodes are in communication with an impedance meter 504 that measures the impedance between the electrodes 502 a and 502 b .
  • the impedance meter 504 may be in communication with a processor 506 . As will be explained in detail below, the processor 506 controls various aspects of the device 500 .
  • the processor 506 is in communication with a first memory device 508 for storing a reference database 510 .
  • the first memory device may be a conventional memory chip.
  • the processor 506 may be in communication with a second memory device 507 for the storage of temporary variables and measured data.
  • the second memory device 507 may be either built into the processor or as an external chip.
  • the processor 506 may also be in communication with a user interface 509 , which may take a variety of embodiments, such as a screen and input device.
  • the processor 506 may also be in communication with a digital-to-analog converter 512 which converts digital signals from the processor to the analog signals.
  • the analog signals may be sent to an amplifier 514 which is adapted to send signals to the electrodes 502 a and 502 b .
  • a reset signal generator 516 is also in communication with the electrodes 502 a and 502 b and is adapted to send signals to the electrodes.
  • the signal generator 516 may also be in communication with the processor 506 .
  • the signal generator 516 is adapted to alternate polarity of the signal to electrodes and the amplifier 514 .
  • the signal generator may be a reset circuit similar to the reset circuit 30 discussed in reference to FIG. 1 a.
  • the user interface 509 may send a signal to the processor 106 to initiate a process.
  • the processor 506 initiates a process which causes the impedance meter 504 to read the impedance between the electrodes 502 a and 502 b .
  • the impedance meter 504 amplifies the impedance signal, digitizes the impedance signal and sends it back to the processor 506 .
  • the processor uses the initial impedance reading to calculate a gain factor which may be stored in the memory 507 for later use.
  • the processor 506 then initiates a process which reads the database 510 stored in the memory 508 .
  • the codes or signature signals from the database 510 are then sent to the digital-to-analog converter 512 , which converts the digital signals to analog signals.
  • the analog signals may then sent to the amplifier 514 , which amplifies the analog signal and sends the signals to the electrodes 502 a and 502 b .
  • the impedance between the electrodes 502 a and 502 b may then be read by the impedance meter 504 .
  • the substance amount in the organism may then be determined according to the iterative processes similar to those discussed above.
  • FIG. 6 a illustrates an example embodiment of a system 600 which is designed to be worn on a person's wrist.
  • a portable measurement device 602 which is adapted to be coupled to wrist bands 604 a and 604 b .
  • the measurement device 602 may contain all of the components discussed previously in reference to FIGS. 1 a through 1 c or FIG. 5 .
  • FIG. 6 b is an exploded perspective view of the portable device 602 illustrated in FIG. 6 a .
  • the measurement device 602 includes a user interface which comprises a touch screen 606 and a liquid crystal display (LCD) 608 .
  • the touch screen 606 accepts input from a user and the LCD 608 displays information and the results of processing.
  • there are housing members 610 a and 610 b which encloses the various components, such as the processor and memory devices previously discussed.
  • the components may be assembled on a printed circuit board 612 .
  • a power source such as a lithium battery 614 provides the device with the necessary power.
  • Electrodes 616 a and 616 b may be located on underside of watch and are adapted to touch the back side of a human wrist.
  • the electrodes 616 a and 616 b are made from a conductive material, such as copper, gold, silver, metal, stainless steel or any combination thereof.
  • the electrodes 616 a and 616 b may be spaced to line up over acupuncture points of endocrine or lymphatic system meridian.
  • there is method of determining a substance in a living organism comprising: applying an electrical signature signal to the living organism, wherein the electrical signature signal corresponds to a predetermined amount of the substance; measuring the response of the living organism to the applied signature signal; and determining whether an elevated response has resulted from applying the electrical signature, if so, then determining the amount of the substance in the living organism from the predetermined amount of the substance.
  • each signature signal in the plurality of signature signals corresponds to a different predetermined amount of the substance.
  • the plurality of signature signals correspond to a predetermined amount of the substance ranging from a low amount of the substance to a high amount of the substance.
  • the measuring the response comprises measuring the impedance between two different points on the skin of the living organism.
  • the measuring the response comprises: measuring a plurality of impedance values over time resulting from applying the signature signal corresponding to a predetermined amount of the substance to establish a first data set of measure data values; reapplying the electrical signature signal to the living organism; measuring a plurality of impedance values over time resulting from applying the signature signal to establish a second data set of measure data values.
  • the determining comprises: determining whether there is convergence between the first and second data sets; if there is convergence between the first and second data sets, then storing the data sets as a candidate set.
  • an apparatus for measuring a substance in a living organism characterized by: a processor means; at least two electrode means for applying and receiving signals, an impedance measuring means for determining the impedance between the at least two electrode means; a memory means for storing a database of electrical signature signals, wherein each electrical signature signal corresponds to different amounts of a substance; and a means for applying the electrical signature signals to the at least two electrode means.
  • an apparatus similar to that described above, further characterized by an amplifier means for amplifying signals from the impedance determining means; and an analog-to-digital conversion means for converting analog signals from the amplifier means to digital signals.
  • a gain adjusting means for adjusting the gain of the amplification means.
  • a housing means for housing components of the measuring apparatus wherein the housing means is adapted for engagement with a strap means.
  • the strap means is a wrist strap means.
  • Electrodes means are made in part from stainless steel.
  • an apparatus similar to that described above further characterized by: an digital-to-analog conversion means for converting digital signals from the memory means; and an amplifier means for amplifying analog signals from the digital-to-analog conversion means.

Abstract

Disclosed are systems and methods of determining the amount of a substance in a living organism. In one embodiment, the method comprises: applying an electrical signature signal to the living organism, wherein the electrical signature signal corresponds to a predetermined amount of the substance; measuring the response of the living organism to the applied signature signal; and determining whether an elevated response has resulted from applying the electrical signature signal, if so, then determining the amount of the substance in the living organism from the predetermined amount of the substance.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a division of, and claims the benefit of the filing date of, co-pending U.S. patent application Ser. No. 11/074,283 entitled “Methods And Devices For Non-Invasively Measuring Quantitative Information Of Substances In Living Organisms,” filed Mar. 6, 2005, which claims the benefit of the filing date of U.S. provisional patent application Ser. No. 60/550,913, entitled “Methods And Devices For Non-Invasively Measuring Quantitative Information Of Substances In Living Organisms,” filed on Mar. 6, 2004, the disclosure of which is incorporated herein by reference.
  • TECHNICAL FIELD
  • The invention relates in general to medical measuring devices and in particular to methods and devices for non-invasively measuring quantitative information of substances in living organisms.
  • BACKGROUND INFORMATION
  • The living organism and its functioning systems are sources of extremely weak electromagnetic oscillations in a broad spectrum of frequencies. Several holistic therapeutic processes take advantage of such principles. These therapeutic processes utilize specific ultra fine oscillation information and are generally known as “bioresonance therapy.”
  • The term bioresonance therapy (“BRT”) was coined in 1987 by the Brugemann Institute for “therapy using the patient's own electromagnetic oscillations.” Such principles can be traced to the physician Dr. F. Morrell, who presented the use of his idea for the first time in 1977. Dr. Morrell's postulated that all disease and their pre-conditions are accompanied or caused by electromagnetic oscillations. According to Dr. Morrell's postulations, there is no pathological phenomenon without the presence of pathological oscillations in or around the body.
  • Pathological electromagnetic oscillations are active alongside the healthy oscillations in the body of every patient. Because the patent's own oscillations or signals are electromagnetic in nature, they can be detected by using electrodes and electromagnetic measurement devices. Using what is known as a separator, the harmonious oscillations, which are virtually identical in all humans, may be filtered out through a filter. Interfering frequencies, which may be caused by pathogens, are not captured by the filter. Thus, the separator only resonates with harmonious frequencies. In this way, it is possible to separate harmonious and disharmonious frequencies.
  • Diabetes is a life threatening disease which affects an estimated 20 million Americans, out of whom 50% are not aware of having it. The latest statistical estimates indicate there are approximately 125 million people diagnosed with diabetes worldwide, and that number is expected to rise 220+million by the year 2010. Early detection of diabetes is manageable allowing those affected to live longer and healthier lives. Blood glucose level monitoring and tracking provides valuable information to help control patients with diabetes. Diabetic people who using insulin regularly need to check the glucose level three or more times per day. This process of monitoring the glucose level allows doctors to have prompt and primary information in detecting the cure for disease.
  • During 1970's monitoring glucose level instruments were invented which based on chemical test strips which could react with drawn blood. Today, there are sophisticated electronic devices which are used to determine blood glucose levels; however, these devices still use invasive techniques to draw a sample of blood from the patient. However such techniques are invasive, inconvenient, and sometimes painful. Rather than use invasive techniques, such as blood tests, it would be desirable to use electromagnetic oscillations to determine the amounts of certain substances, such a blood glucose, within a living organism. Additionally, it would also be useful to use oscillations of various substances to determine the levels of any substance in a living organism.
  • What is needed, therefore, is a method and/or apparatus which can non-invasively test for substances, such as glucose levels in blood or the body in general by using electromagnetic oscillations.
  • SUMMARY
  • The previously mentioned needs are fulfilled with various embodiments of the present invention. Accordingly, in one embodiment, a method and system is provided for non-invasively measuring a level of a substance level in a living organism, the method comprises: measuring the electrical potential between points on different meridians of vegetative system, or between different points on the skin of the organism; storing the measured value as reference point; applying a plurality of low current electrical signals, where each signal corresponds to a previously extracted electrical signal derived from a known concentration of the substance to determine a maximum difference between the reference point and the responses to the electrical signals, then determining the amount of the substance in the living organism by using the maximum difference and previously determined table to correlate the amount of the substance with the maximum difference.
  • In another aspect, there is disclosed a method of determining a substance in a living organism, the method comprising: applying an electrical signature signal to the living organism, wherein the electrical signature signal corresponds to a predetermined amount of the substance; measuring the response of the living organism to the applied signature signal; and determining whether an elevated response has resulted from applying the electrical signature, if so, then determining the amount of the substance in the living organism from the predetermined amount of the substance.
  • In another aspect, the detection of the “body response” is based on the monitoring of the level of convergence of sequentially generated curves of conductivity change versus time for the same substance signature wave applied to the body between two points on the skin.
  • In another aspect, there is a process for the matching of self-oscillation frequencies of different concentrations of glucose molecules in the human blood with similar frequencies of pre-known concentrations of glucose in reference solutions. As a result of such a resonance or “GlucoResonance”, the electrical potential between two predefined acupuncture points (“aculevel”) on a human body changes significantly. This change represents the difference between the measured aculevel with and without GlucoResonance.
  • One aspect uses an internal database of self-oscillation frequencies extracted from hundreds of biological solutions with different levels of glucose, covering the range of blood glucose levels from 10 mg/dl to 600 mg/dl. In order to test for glucose in the blood, a low-current electrical signal for every entry in the reference database may be applied to a patient at predetermined points on the skin or acupuncture points. These electrical signals are applied at points where the electrical potential has been previously measured to establish a calibration aculevel. Then the measured aculevel for every data point is compared with the calibration aculevel. A large disturbance/change between these values suggests the blood glucose level in the patient.
  • In other aspects, there is disclosed an apparatus for measuring a substance in a living organism, the apparatus may comprise: a processor means; at least two electrode means for applying and receiving signals, an impedance measuring means for determining the impedance between the at least two electrode means; a memory means for storing a database of electrical signature signals, wherein each electrical signature signal corresponds to different amounts of a substance; and a means for applying the electrical signature signals to the at least two electrode means.
  • These and other features, and advantages, will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings. It is important to note the drawings are not intended to represent the only form of the invention.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 a is a schematic diagram illustrating one embodiment of the present invention.
  • FIG. 1 b is a schematic diagram illustrating an impedance meter which could be used in various embodiments of the present invention.
  • FIG. 1 c is a schematic diagram illustrating a reset circuit which could be used in various embodiments of the present invention.
  • FIG. 2 illustrates a general process for non-invasively measuring quantitative information of substances in living organisms.
  • FIG. 3 a illustrates a detailed process for non-invasively measuring quantitative information of substances in living organisms.
  • FIG. 3 b is a continuation of the process illustrated in FIG. 3 a.
  • FIGS. 4 a-4 b illustrate graphs of curves which illustrate impedance measurements occurring in the time domain.
  • FIG. 5 is a schematic diagram illustrating another embodiment of the present invention.
  • FIG. 6 a is a perspective view illustrating a portable device incorporating one or more aspects of the present invention.
  • FIG. 6 b is an exploded perspective view of the portable device illustrated in FIG. 6 a.
  • DETAILED DESCRIPTION OF THE INVENTION
  • It is understood, however, that the following disclosure provides many different embodiments, or examples, for implementing different features of the invention. Specific examples of components, signals, messages, protocols, and arrangements are described below to simplify the present disclosure. These are, of course, merely examples and are not intended to limit the invention from that described in the claims. Well-known elements are presented without detailed description in order not to obscure the present invention in unnecessary detail. For the most part, details unnecessary to obtain a complete understanding of the present invention have been omitted in as much as such details are within the skills of persons of ordinary skill in the relevant art. Details regarding control circuitry or mechanisms described herein are omitted; as such control circuits are within the skills of persons of ordinary skill in the relevant art.
  • Acupuncture points are well known in Chinese medicine. In the 1950's, Dr. Reinhard Voll studied acupuncture and learned that the body has about 2000 points on the skin which follow twenty lines called meridians. According to Chinese traditional medicine, meridians are channels of energy and that energy movement is called Qi. Western studies have also shown that acupuncture points may be found by mapping skin electrical resistances. Thus, acupuncture points are specific superficial anatomic locations where the skin on or over these points is lower in electrical resistance than the surround skin, making acupuncture points strategic conductors of electromagnetic signals in the body. Some studies have shown that acupuncture point resistance is approximately half that of the surrounding skin (or conductance is twice as higher). It is possible, therefore, to measure the galvanic skin or other paths' resistance or conductance at the acupuncture points to determine the resonance point of self oscillating frequency of the organism. In this case the human body is becoming the main detector of resonance point, while the conductance between any two different points on the body can be a secondary sensor of the body reaction to the resonance event.
  • As discussed previously, in certain methods of therapy, disharmonious frequencies (e.g., the signature frequency of certain pathogens) may be filtered out and inverted. These inverted frequencies as well as harmonious oscillations from the separator may be fed back to the patient using an electrode. The patient's own electromagnetic field reacts to the therapy signals and in turn enters a modified pattern into the measurement devices and separator. This process may be repeated and thus the pathological signals in the body are consequently reduced and finally extinguished. It has been shown that eliminating the pathological signals from the body has a beneficial therapeutic effect.
  • One aspect of the present invention recognizes that certain substances, such as glucose also have a particular electromagnetic oscillation or frequency. For purposes of this application, a “substance” is matter of a particular or definite chemical composition, such as glucose. The oscillations associated with a particular substance may change as the amount of the substance changes within an organism. Thus, various aspects of the present invention use electromagnetic oscillations to determine the substance concentration, such a blood glucose, within a living organism.
  • As previously discussed, every substance also has its own magnetic “self” frequency oscillation. When the frequency of a reagent is introduced into the organism through an electrode, the frequency of the reagent interacts with the frequency of the organism and creates a change in amplitude of the frequency. The response or change in amplitude or “excitation” of the signal can be detected and measured. Thus, it is possible to determine which signal frequencies produces the greatest excitation when compared to the reference point (the reference point can be also a first conductance/resistance measurement applying the same reagent signature). When comparing a plurality of frequencies (each frequency corresponds to a known level of the substance), the frequency that produces the greatest excitation is the frequency that corresponds to the level of the substance in the organism.
  • Thus, for every reference correlation in a reference database, a low-current electrical signal having a particular frequency may be introduced into the organism, which is applied at acupressure points or any other points on the human body where the electrical potential has been previously measured. This process may be repeated for every correlation in the reference database until a match (e.g. the signal that produces the greatest excitation) is found.
  • Turning now to FIG. 1 a, there is illustrated one aspect of the present invention. In this aspect, there is a measuring device 10 for measuring the levels of a substance in a living organism. The measuring device 10 comprises a user interface 12. The user interface 12 may comprise one or more interfaces which are capable of receiving input and presenting output to a user or software agent. Specific aspects of the user interface 12 may include a display, a touch sensitive input screen, input keys, microphones and/or speakers (not shown).
  • The user interface 12 may be in communication with a processor 14. In certain aspects of the present invention, the processor 14 controls the processes and various functions of the measuring device 10. In some aspects of the present invention, the processor 14 may be coupled to a first memory 16. The memory 16 may be built into the processor 14 or be an external memory chip. In certain aspects of the present invention, the processor 14 may also be in communication with a second memory 18. The second memory 18 may be an external memory chip or memory built into the processor 14. In certain embodiments, the second memory may contain a reference database 20, such as a database of extracted glucose reagent signatures.
  • In one embodiment, the reference database 20 may be a table of values correlating reference or signature frequencies to specific levels of a substance in a “reagent.” As used in this application, a reagent is a substance typically mixed with a liquid or solvent to form a compound. The reagent may be selected because of its biological or chemical activity. As will be explained later, the reagent may be used to determine the self oscillating frequency of a substance. By using empirical techniques, a table of correlating the self oscillating frequencies to amounts of a substance in a reagent may be built and loaded into the database 20.
  • The memory 18 may be in communication with a pair of electrodes 22 a and 22 b. In certain embodiments, one electrode may be active-positive and the other electrode may be passive-negative. As will be explained later, the electrodes 22 a and 22 b are adapted to interact with the skin of the organism and may be used to measure the impedance between two points on the skin. In certain embodiments, the electrodes are in communication with an impedance meter 24 which determines or measures the impedance between the electrodes 22 a and 22 b. The impedance meter 24 may be in communication with an amplifier 26, which amplifies signals sent from the impedance meter 24.
  • In the illustrative embodiment, the amplifier 26 may in communication with an analog-to-digital converter 28 which converts analog signals from the amplifier to the digital signals. In some embodiments, the digital signals may be sent to the processor 14.
  • A reset circuit 30 may also be coupled to the measuring device 10 and in communication with the processor 14. The reset circuit 30 may also in communication with the electrodes 22 a and 22 b. In some embodiments, the reset circuit 30 may be adapted to clear or “short out” any residual charge between the electrodes. In other words, the reset circuit 30 clears any residual capacitance and/or changes polarization which may have developed on the skin between the electrodes. The measuring device 10 may be powered by a power source, such as a battery (not shown).
  • Turning now to FIG. 1 b, there is illustrated one embodiment of the impedance meter 24. In this embodiment, a circuit 39 determines the relative change of impedance between two electrodes outputs a corresponding voltage which represents the change in impedance. In this embodiment, the circuit 39 may comprise leads 40 a and 40 b to the electrodes 22 a and 22 b (FIG. 1), respectively. The lead 40 a may be coupled to the negative or inverting input of an operational amplifier 42. The positive or non-inverting input of the operational amplifier 42 may be coupled to a partial circuit comprising a resister 44, a common ground 46, a voltage reference 48, and a resistor 50. The positive lead of the voltage reference 48 and the negative lead of the resistor 50 may be coupled to a resistor 52. The resistor 52 may be coupled to the lead 40 a and the negative input of the operational amplifier 42.
  • In this illustrative embodiment, the lead 40 b is coupled to the output of the operational amplifier 42. A resistor 54 also couples the leads 40 a to the lead 40 b. The output of the operational amplifier 42 sends a voltage to a variable gain amplifier 56, which is also adapted to receive signals from the processor 14 (FIG. 1). Thus, the circuit 39 sends a voltage to the variable gain amplifier 56 which corresponds to the change in impedance between the electrodes. The variable gain amplifier 56 amplifies the voltage and sends the amplified signal to an analog-to-digital converter 58. In the illustrative embodiment, the analog-to-digital converter 58 converts the analog signals from the variable gain amplifier 56 and sends the converted digital signals to the processor 14.
  • Turning now to FIG. 1 c, there is illustrated one aspect of the reset circuit 30. In this illustrative embodiment, there is a generic analog switch 60 adapted to receive input commands from the processor 14 (FIG. 1) from a lead 62. The analog switch 60 may also be in communication with the electrodes 22 a and 22 b (FIG. 1) through the leads 64 a and 64 b, respectively. Upon receiving the appropriate command from the processor 14, the analog switch 60 is thrown, which effectively “shorts” out any residual charge between the electrodes. In other embodiments (not shown), the circuit may be adapted to alternate the polarity of the electrodes 22 a and 22 b.
  • FIG. 2 illustrates a general method 200 to determine the amount of a particular substance in an organism, such as a human body. The process starts at step 202 and proceeds to step 204 where an electrical signature wave or signal corresponding to one frequency is applied to the electrodes (e.g., electrodes 22 a and 22 b of FIG. 1) which may be in contact with the skin of the organism. The applied electrical signature signal correlates to a predetermined concentration of the substance. In some aspects of the method, there is a pre-existing reference database (e.g., database 20 of FIG. 1) stored on a conventional memory chip containing correlations between “signature” signal frequencies (e.g., 22-44 kilohertz) and known concentrations of a substance reagent. Thus, each signature frequency in the database correlates to a known concentration of a substance in an organism.
  • In step 206, a response or “excitation” to the applied signature signal is measured. In step 208, the process determines whether the response is “elevated.” In other words, did the organism respond in such a way as to indicate a positive correlation between applied electrical signal and the known concentration of the substance. If it is determined that the response to the applied electrical signature is elevated, then the process flows to step 210 where a correlation may be made between to determine the level of the substance (such as glucose) in the organism. On the other hand, if there is not an elevated response, the process may flow back to step 204, where, in some embodiments, a new electrical signature wave may be applied.
  • As will be explained below, in some embodiments, the process may iteratively apply a plurality of electrical signature signals, where each signal corresponds to a particular concentration of a substance. The electrical signature signal (or signals) that caused the greatest amount of excitation may be determined and the reference database may be again accessed to determine the particular level of the substance that corresponds with the frequency. The level of the substance can, therefore, be determined and displayed through a user interface.
  • As an example, the self-oscillation frequencies of different concentrations of glucose molecules in the human blood can be matched with similar frequencies of pre-known concentrations of glucose in reference solutions. Once a frequency is matched, the corresponding glucose level in the blood can be readily determined.
  • FIGS. 3 a and 3 b illustrate a detailed exemplary embodiment of the general method illustrated in FIG. 2. The process starts in step 302. In certain embodiments, a signal from the user interface initiates the process. In other aspects, the process may be initiated by the processor as a result of a preprogrammed schedule or timer circuit. After initiation, the process then proceeds to step 304 where the electrical impedance between two different points on the skin is measured via the electrodes 22 a and 22 b. In certain embodiments, the two points may be acupuncture points which lie on different meridians. At step 306, the process determines whether the impedance signal (e.g., the voltage representing the impedance) is within acceptable predetermined limits. For instance, if the readings from the impedance measurement is too low, the amplifier gain may be adjusted. If the readings are not within the predetermined limits, in step 308, a gain factor is calculated. In step 310, the gain factor may be stored in memory for later use in making additional impedance measurements. In step 312, the gain factor may be used to adjust the gain of the amplifier. The process then flows back to step 304 where the impedance is again measured. At step 306, the process determines whether the new impedance signal is within acceptable predetermined limits. Once it has been determined the signal is within acceptable limits, process flows to step 314.
  • In step 314, a first signature signal from the reference database 20 is applied on the electrodes. In some embodiments, the signature wave corresponds to a known level of glucose. In step 316, a series of measurements of the electrical impedance is then performed in the time domain which creates a first data set. The first data set may be represented by a curve 402 on the graph illustrated in FIG. 4a. In FIG. 4a, the vertical axis represents the response or measured impedance. The horizontal axis represents time. Thus, the curve 402 represents the impedance response over time resulting from the application of the signature signal which is applied at time=0. In other words, each point on the curve represents the measured value of impedance at a particular time from the occurrence of the application of the signature signal.
  • Turning back to FIG. 3, in step 318, the residual voltage on the electrodes may then be cleared as discussed in reference to FIG. 1 c. In step 320, the signature signal is again applied through the electrodes. This is the same signal which was applied in step 314. In step 322, another series of measures of the electrical impedance is performed in the time domain which creates a second data set. The second data set may be represented by curve 404 of the graph illustrated in FIG. 4 b. In certain embodiments, the steps 314 through 322 may be repeated to produce additional data sets if predefined indicators, such as quality-of-measurement indicators, are not met.
  • In step 324, the data sets are compared to each other to determine whether convergence has been achieved. The amount of convergence may be graphically represented by the graph illustrated in FIG. 4c which shows curve 402 superimposed onto curve 404. If convergence has not been achieved, the process flows directly to step 328. If convergence has been achieved, then in step 326, the process stores the signature sets as a candidate data set before it flows to step 328.
  • In step 328, the process determines whether all of the signature signals in the database have been applied. If not, the process flows to step 330 (FIG. 3a), where the residual voltage is removed as discussed in reference to FIG. 1 c. From step 330, the process flows to step 332, where the next signature signal in the database is set up to be applied to the electrodes. The process then flows back to step 314, where the steps 314 through 328 are repeated for the new signature signal. On the other hand, if in step 328, it is determined that all of the signature signals have been applied to the electrodes, the process flows to step 334.
  • In step 334, the logic reviews the stored candidate data sets to determine the set having the maximum convergence or the “best” candidate out of the stored candidate data sets. Using the frequency responsible for producing the best candidate, in step 336, the reference database may then be accessed to determine the level of the substance that corresponds with the signal. The level of the substance can, therefore, be determined and sent to a user interface. The process ends at step 338.
  • Turning now to FIG. 5, there is an alternative measuring device 500 for measuring the levels of a substance in a living organism. The measuring device 500 comprises a pair of electrodes 502 a and 502 b. One electrode is active-positive and the other electrode is passive-negative. The electrodes 502 a and 502 b are adapted to interact with the skin of the organism and may measure the electro conductivity between two points on the skin, such as two points on different meridians. The electrodes are in communication with an impedance meter 504 that measures the impedance between the electrodes 502 a and 502 b. The impedance meter 504 may be in communication with a processor 506. As will be explained in detail below, the processor 506 controls various aspects of the device 500. The processor 506 is in communication with a first memory device 508 for storing a reference database 510. In some embodiments, the first memory device may be a conventional memory chip. In other embodiments, the processor 506 may be in communication with a second memory device 507 for the storage of temporary variables and measured data. The second memory device 507 may be either built into the processor or as an external chip. The processor 506 may also be in communication with a user interface 509, which may take a variety of embodiments, such as a screen and input device.
  • In some embodiments, the processor 506 may also be in communication with a digital-to-analog converter 512 which converts digital signals from the processor to the analog signals. In some embodiments, the analog signals may be sent to an amplifier 514 which is adapted to send signals to the electrodes 502 a and 502 b. A reset signal generator 516 is also in communication with the electrodes 502 a and 502 b and is adapted to send signals to the electrodes. The signal generator 516 may also be in communication with the processor 506. In certain embodiments, the signal generator 516 is adapted to alternate polarity of the signal to electrodes and the amplifier 514. In other embodiments, the signal generator may be a reset circuit similar to the reset circuit 30 discussed in reference to FIG. 1 a.
  • As in the embodiment discussed in reference to FIG. 1 a, the user interface 509 may send a signal to the processor 106 to initiate a process. In response, the processor 506 initiates a process which causes the impedance meter 504 to read the impedance between the electrodes 502 a and 502 b. The impedance meter 504, amplifies the impedance signal, digitizes the impedance signal and sends it back to the processor 506. The processor uses the initial impedance reading to calculate a gain factor which may be stored in the memory 507 for later use.
  • The processor 506 then initiates a process which reads the database 510 stored in the memory 508. The codes or signature signals from the database 510 are then sent to the digital-to-analog converter 512, which converts the digital signals to analog signals. The analog signals may then sent to the amplifier 514, which amplifies the analog signal and sends the signals to the electrodes 502 a and 502 b. The impedance between the electrodes 502 a and 502 b may then be read by the impedance meter 504. The substance amount in the organism may then be determined according to the iterative processes similar to those discussed above.
  • FIG. 6 a illustrates an example embodiment of a system 600 which is designed to be worn on a person's wrist. As illustrated, there is a portable measurement device 602 which is adapted to be coupled to wrist bands 604 a and 604 b. The measurement device 602 may contain all of the components discussed previously in reference to FIGS. 1 a through 1 c or FIG. 5.
  • FIG. 6 b is an exploded perspective view of the portable device 602 illustrated in FIG. 6 a. In this embodiment, the measurement device 602 includes a user interface which comprises a touch screen 606 and a liquid crystal display (LCD) 608. The touch screen 606 accepts input from a user and the LCD 608 displays information and the results of processing. In this example embodiment, there are housing members 610 a and 610 b which encloses the various components, such as the processor and memory devices previously discussed. In this embodiment, the components may be assembled on a printed circuit board 612. In this particular example, a power source, such as a lithium battery 614 provides the device with the necessary power. Electrodes 616 a and 616 b may be located on underside of watch and are adapted to touch the back side of a human wrist. In certain embodiments, the electrodes 616 a and 616 b are made from a conductive material, such as copper, gold, silver, metal, stainless steel or any combination thereof. In the illustrated embodiment, the electrodes 616 a and 616 b may be spaced to line up over acupuncture points of endocrine or lymphatic system meridian.
  • The foregoing description of the embodiments of the invention has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in light of the above teaching. It is intended that the scope of the invention be limited not by this detailed description, but rather by the claims appended hereto.
  • For instance, in some embodiments, there is method of determining a substance in a living organism, the method comprising: applying an electrical signature signal to the living organism, wherein the electrical signature signal corresponds to a predetermined amount of the substance; measuring the response of the living organism to the applied signature signal; and determining whether an elevated response has resulted from applying the electrical signature, if so, then determining the amount of the substance in the living organism from the predetermined amount of the substance.
  • There may also be a method similar to that described above, further comprising providing a plurality of electrical signal signals, wherein each signature signal in the plurality of signature signals corresponds to a different predetermined amount of the substance.
  • There may also be a method similar to that described above, wherein the plurality of signature signals correspond to a predetermined amount of the substance ranging from a low amount of the substance to a high amount of the substance.
  • There may also be a method similar to that described above, wherein the method of claim 1 is repeated for each electrical signature signal in the plurality of electrical signature signals.
  • There may also be a method similar to that described above, wherein the substance is glucose.
  • There may also be a method similar to that described above, wherein the measuring the response comprises measuring the impedance between two different points on the skin of the living organism.
  • There may also be a method similar to that described above, wherein the measuring the response comprises: measuring a plurality of impedance values over time resulting from applying the signature signal corresponding to a predetermined amount of the substance to establish a first data set of measure data values; reapplying the electrical signature signal to the living organism; measuring a plurality of impedance values over time resulting from applying the signature signal to establish a second data set of measure data values.
  • There may also be a method similar to that described above, further comprising clearing any residual charges between the points on the skin.
  • There may also be a method similar to that described above, wherein the determining comprises: determining whether there is convergence between the first and second data sets; if there is convergence between the first and second data sets, then storing the data sets as a candidate set.
  • There may also be a method similar to that described above, further comprising: examining each stored candidate set to determine the candidate set having the largest convergence, and setting the amount of the substance to be the signature that corresponds to the candidate set having the largest convergence.
  • In other embodiments, there may be an apparatus for measuring a substance in a living organism, the apparatus characterized by: a processor means; at least two electrode means for applying and receiving signals, an impedance measuring means for determining the impedance between the at least two electrode means; a memory means for storing a database of electrical signature signals, wherein each electrical signature signal corresponds to different amounts of a substance; and a means for applying the electrical signature signals to the at least two electrode means.
  • There may also be an apparatus similar to that described above, further characterized by an amplifier means for amplifying signals from the impedance determining means; and an analog-to-digital conversion means for converting analog signals from the amplifier means to digital signals.
  • There may also be an apparatus similar to that described above, further characterized by a gain adjusting means for adjusting the gain of the amplification means.
  • There may also be an apparatus similar to that described above, further characterized by a memory means for storing a gain factor determined from the gain adjusting means.
  • There may also be an apparatus similar to that described above, further characterized by a reset means for discharging any residual voltage between the at least two electrode means.
  • There may also be an apparatus similar to that described above, further characterized by a housing means for housing components of the measuring apparatus, wherein the housing means is adapted for engagement with a strap means.
  • There may also be an apparatus similar to that described above, wherein the strap means is a wrist strap means.
  • There may also be an apparatus similar to that described above, wherein the electrode means are made in part from stainless steel.
  • There may also be an apparatus similar to that described above, wherein the substance is glucose.
  • There may also be an apparatus similar to that described above, further characterized by: an digital-to-analog conversion means for converting digital signals from the memory means; and an amplifier means for amplifying analog signals from the digital-to-analog conversion means.
  • The abstract of the disclosure is provided for the sole reason of complying with the rules requiring an abstract, which will allow a searcher to quickly ascertain the subject matter of the technical disclosure of any patent issued from this disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

Claims (7)

1. An apparatus for measuring a substance in a living organism, the apparatus comprising:
a processor in communication with at least one memory device; a memory device in communication with the processor, wherein the memory device includes a database of electrical signature signals, wherein each electrical signature signal corresponds to different amounts of the substance in the living organism;
an impedance meter in communication with the processor;
at least two electrodes coupled to the impedance meter such that the impedance meter can measure the impedance between the at least two electrodes, wherein the at least two electrodes are also coupled to the memory device;
a signal amplifier in communication with the processor and the impedance meter, wherein the signal amplifier is adapted to amplify signals from the impedance meter;
an analog-to-digital converter in communication with the amplifier and the processor, wherein the analog-to-digital converter is adapted to convert analog signals from the amplifier to digital signals before sending the digital signals to the processor;
a reset circuit in communication with the processor and coupled to the at least two electrodes.
2. The apparatus of claim 1, wherein the impedance meter further comprises:
an impedance indicator circuit for producing a voltage representing the impedance between the at least two electrodes;
an amplifier in communication with the impedance indicator circuit, wherein the amplifier is adapted to amplify the voltage from the impedance indicator circuit; and
an analog-to-digital converter in communication with the amplifier and the processor, wherein the analog-to-digital converter is adapted for converting analog signals from the amplifier to digital signals.
3. The apparatus of claim 1, wherein the reset circuit is adapted to discharge residual voltage between the at least two electrodes.
4. The apparatus of claim 1, wherein the reset circuit is adapted to change the polarity of the at least two electrodes.
5. The apparatus of claim 1, further comprising a housing which partially surrounds the processor, wherein the housing is adapted for engagement with a strap means such that the apparatus may be worn on a wrist.
6. The apparatus of claim 1, wherein the at least two electrodes are made in part from the group consisting of copper, gold, silver, metal and stainless steel.
7. The apparatus of claim 1, further comprising a user interface, wherein the user interface comprises a touch screen and a flat screen display.
US11/680,927 2004-03-06 2007-03-01 Methods and devices for non-invasively measuring quantitative information of substances in living organisms Abandoned US20070149876A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/680,927 US20070149876A1 (en) 2004-03-06 2007-03-01 Methods and devices for non-invasively measuring quantitative information of substances in living organisms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55091304P 2004-03-06 2004-03-06
US11/074,283 US7395104B2 (en) 2004-03-06 2005-03-06 Methods and devices for non-invasively measuring quantitative information of substances in living organisms
US11/680,927 US20070149876A1 (en) 2004-03-06 2007-03-01 Methods and devices for non-invasively measuring quantitative information of substances in living organisms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/074,283 Division US7395104B2 (en) 2004-03-06 2005-03-06 Methods and devices for non-invasively measuring quantitative information of substances in living organisms

Publications (1)

Publication Number Publication Date
US20070149876A1 true US20070149876A1 (en) 2007-06-28

Family

ID=34976112

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/074,283 Expired - Fee Related US7395104B2 (en) 2004-03-06 2005-03-06 Methods and devices for non-invasively measuring quantitative information of substances in living organisms
US11/680,907 Abandoned US20070156040A1 (en) 2004-03-06 2007-03-01 Methods and devices for non-invasively measuring quantitative information of substances in living organisms
US11/680,927 Abandoned US20070149876A1 (en) 2004-03-06 2007-03-01 Methods and devices for non-invasively measuring quantitative information of substances in living organisms

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/074,283 Expired - Fee Related US7395104B2 (en) 2004-03-06 2005-03-06 Methods and devices for non-invasively measuring quantitative information of substances in living organisms
US11/680,907 Abandoned US20070156040A1 (en) 2004-03-06 2007-03-01 Methods and devices for non-invasively measuring quantitative information of substances in living organisms

Country Status (11)

Country Link
US (3) US7395104B2 (en)
EP (1) EP1722681A4 (en)
JP (1) JP2007527750A (en)
KR (1) KR20060129507A (en)
CN (1) CN1925786A (en)
AU (1) AU2005220794A1 (en)
CA (1) CA2558239A1 (en)
EA (1) EA200601463A1 (en)
IL (1) IL177889A0 (en)
TW (1) TW200535416A (en)
WO (1) WO2005086725A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177451A1 (en) * 2012-05-25 2013-11-28 Qualcomm Incorporated Methods and devices for acquiring electrodermal activity
US8781565B2 (en) 2011-10-04 2014-07-15 Qualcomm Incorporated Dynamically configurable biopotential electrode array to collect physiological data
US9378655B2 (en) 2012-12-03 2016-06-28 Qualcomm Incorporated Associating user emotion with electronic media

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6697658B2 (en) 2001-07-02 2004-02-24 Masimo Corporation Low power pulse oximeter
US6989891B2 (en) 2001-11-08 2006-01-24 Optiscan Biomedical Corporation Device and method for in vitro determination of analyte concentrations within body fluids
CN1925786A (en) * 2004-03-06 2007-03-07 卡里斯托医药有限公司 Methods and devices for non-invasively measuring quantitative information of substances in living organisms
US8190223B2 (en) 2005-03-01 2012-05-29 Masimo Laboratories, Inc. Noninvasive multi-parameter patient monitor
WO2007053963A1 (en) * 2005-11-10 2007-05-18 Solianis Holding Ag Device for determining the glucose level in body tissue
US7937140B2 (en) * 2006-06-12 2011-05-03 Regni Jr Gerald J Detection and diagnostic system and method
US20080077073A1 (en) * 2006-08-15 2008-03-27 Richard Keenan Analyte detection system with user interface providing event entry
US20090187232A1 (en) * 2008-01-16 2009-07-23 Issa Salim Systems And Methods For Therapeutic Treatments
US8682425B2 (en) * 2008-01-30 2014-03-25 Miridia Technology Inc. Electroacupuncture system
US20090270756A1 (en) * 2008-04-23 2009-10-29 Gamache Ronald W Determining physiological characteristics of animal
US8577431B2 (en) 2008-07-03 2013-11-05 Cercacor Laboratories, Inc. Noise shielding for a noninvasive device
US8630691B2 (en) 2008-08-04 2014-01-14 Cercacor Laboratories, Inc. Multi-stream sensor front ends for noninvasive measurement of blood constituents
RU2537083C2 (en) 2009-06-09 2014-12-27 Байосенсорс, Инк. Non-invasive control of blood metabolite level
US20140148726A1 (en) * 2010-10-21 2014-05-29 Timothy Andrew WAGNER Methods for detecting a condition
TWI450707B (en) * 2010-11-09 2014-09-01 Univ Chung Hua Bio-impedance measurement apparatus and assembly
CA2819461A1 (en) 2010-11-30 2012-06-07 Newlife Sciences Llc Apparatus and method for treatment of pain with body impedance analyzer
US20130261420A1 (en) * 2011-06-06 2013-10-03 Semen Kucherov System and method for non-invasive diagnostic of mammals
CN103892843A (en) * 2012-12-27 2014-07-02 龙华科技大学 Non-intrusive blood glucose measurer
US9462949B2 (en) * 2014-07-31 2016-10-11 Chung Hua University Method for biomedical system
CN104545910B (en) * 2014-12-29 2017-08-22 深圳市前海安测信息技术有限公司 Chronic disease early stage electro physiology detection method and system
US11471109B2 (en) * 2015-07-09 2022-10-18 Capsuletech, Inc. Methods and devices for recovering data from an amplitude-modulated signal
US11197628B2 (en) * 2015-07-10 2021-12-14 Bodyport Inc. Cardiovascular health monitoring device
US11696715B2 (en) 2015-07-10 2023-07-11 Bodyport Inc. Cardiovascular signal acquisition, fusion, and noise mitigation
CN105011946B (en) * 2015-07-22 2018-05-04 通普生物科技(北京)有限公司 The method for measuring blood glucose value
EP3983051A1 (en) 2019-06-12 2022-04-20 Truerelief, LLC System and method for delivering pulsed electric current to living tissue
EP3782546B1 (en) * 2019-08-20 2024-02-28 Rayonex Biomedical GmbH Method for identifying an acupuncture point and/or a meridian
US11324423B2 (en) * 2019-08-27 2022-05-10 eTouch Medical Inc. Non-invasive system for testing blood sugar and method of the same
US20210369134A1 (en) * 2020-06-01 2021-12-02 Wellness Allied Inc Device and method to measure meridian impedances
US11911605B2 (en) 2021-03-05 2024-02-27 Truerelief Llc Method and apparatus for injury treatment

Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US455271A (en) * 1891-06-30 Shingles
US3316896A (en) * 1962-10-18 1967-05-02 Thomasset Auguste Louis Apparatus and methods for the measure of the electrical impedance of living organisms
US3608543A (en) * 1968-10-03 1971-09-28 Univ Carnegie Mellon Physiological impedance-measuring apparatus
US3971366A (en) * 1974-11-25 1976-07-27 Hiroshi Motoyama Apparatus and method for measuring the condition of the meridians and the corresponding internal organs of the living body
US4016870A (en) * 1975-10-14 1977-04-12 Chuck Lock Electronic acupuncture point finder
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
US4392933A (en) * 1978-10-31 1983-07-12 Matsushita Electric Industrial Co., Ltd. Electrochemical measuring apparatus comprising enzyme electrode
US4408617A (en) * 1980-01-21 1983-10-11 Deloffre Auguste Apparatus for detecting the acupuncture points on a patient and for applying electrical stimulating signals to the detected points
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4494552A (en) * 1980-08-08 1985-01-22 R2 Corporation Physiological monitoring electrode system
US4539640A (en) * 1982-01-12 1985-09-03 Tasc Ltd. Reconstruction system and methods for impedance imaging
US4655225A (en) * 1985-04-18 1987-04-07 Kurabo Industries Ltd. Spectrophotometric method and apparatus for the non-invasive
US4690152A (en) * 1985-10-23 1987-09-01 American Mediscan, Inc. Apparatus for epithelial tissue impedance measurements
US4714080A (en) * 1986-10-06 1987-12-22 Nippon Colin Co., Ltd. Method and apparatus for noninvasive monitoring of arterial blood oxygen saturation
US4882492A (en) * 1988-01-19 1989-11-21 Biotronics Associates, Inc. Non-invasive near infrared measurement of blood analyte concentrations
US4883953A (en) * 1987-11-17 1989-11-28 Kurashiki Boseki Kabushiki Kaisha Spectroscopic method and apparatus for measuring sugar concentrations
US4897162A (en) * 1986-11-14 1990-01-30 The Cleveland Clinic Foundation Pulse voltammetry
US4911175A (en) * 1987-09-17 1990-03-27 Diana Twyman Method for measuring total body cell mass and total extracellular mass by bioelectrical resistance and reactance
US4947862A (en) * 1988-10-28 1990-08-14 Danninger Medical Technology, Inc. Body composition analyzer
US5028787A (en) * 1989-01-19 1991-07-02 Futrex, Inc. Non-invasive measurement of blood glucose
US5036861A (en) * 1990-01-11 1991-08-06 Sembrowich Walter L Method and apparatus for non-invasively monitoring plasma glucose levels
US5050612A (en) * 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5063937A (en) * 1990-09-12 1991-11-12 Wright State University Multiple frequency bio-impedance measurement system
US5070874A (en) * 1990-01-30 1991-12-10 Biocontrol Technology, Inc. Non-invasive determination of glucose concentration in body of patients
US5077476A (en) * 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
US5086229A (en) * 1989-01-19 1992-02-04 Futrex, Inc. Non-invasive measurement of blood glucose
US5115133A (en) * 1990-04-19 1992-05-19 Inomet, Inc. Testing of body fluid constituents through measuring light reflected from tympanic membrane
US5131401A (en) * 1990-09-10 1992-07-21 Axon Medical Inc. Method and apparatus for monitoring neuromuscular blockage
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
US5146091A (en) * 1990-04-19 1992-09-08 Inomet, Inc. Body fluid constituent measurement utilizing an interference pattern
US5163439A (en) * 1986-11-05 1992-11-17 Dardik Irving I Rhythmic biofeedback technique
US5170199A (en) * 1990-07-09 1992-12-08 Fuji Photo Film Co., Ltd. Lens-fitted photographic film unit
US5197951A (en) * 1983-12-14 1993-03-30 Mahurkar Sakharam D Simple double lumen catheter
US5222496A (en) * 1990-02-02 1993-06-29 Angiomedics Ii, Inc. Infrared glucose sensor
US5222495A (en) * 1990-02-02 1993-06-29 Angiomedics Ii, Inc. Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths
US5267152A (en) * 1989-10-28 1993-11-30 Yang Won S Non-invasive method and apparatus for measuring blood glucose concentration
US5322063A (en) * 1991-10-04 1994-06-21 Eli Lilly And Company Hydrophilic polyurethane membranes for electrochemical glucose sensors
US5339827A (en) * 1993-02-11 1994-08-23 Intech Scientific, Inc. Acupuncture system and method
US5360004A (en) * 1992-12-09 1994-11-01 Diasense, Inc. Non-invasive determination of analyte concentration using non-continuous radiation
US5368028A (en) * 1989-08-11 1994-11-29 Cb-Carmel Biotechnology Ltd. System for monitoring and controlling blood and tissue constituent levels
US5372141A (en) * 1992-07-01 1994-12-13 Body Composition Analyzers, Inc. Body composition analyzer
US5379764A (en) * 1992-12-09 1995-01-10 Diasense, Inc. Non-invasive determination of analyte concentration in body of mammals
US5433197A (en) * 1992-09-04 1995-07-18 Stark; Edward W. Non-invasive glucose measurement method and apparatus
US5568049A (en) * 1993-10-22 1996-10-22 The United States Of America As Represented By The Secretary Of The Navy Fiber optic faraday flux transformer sensor and system
US5590650A (en) * 1994-11-16 1997-01-07 Raven, Inc. Non-invasive medical monitor system
US5720296A (en) * 1995-06-24 1998-02-24 Cha; Ki Chul Apparatus and method for analyzing body composition based on bioelectrical impedance analysis
US5725480A (en) * 1996-03-06 1998-03-10 Abbott Laboratories Non-invasive calibration and categorization of individuals for subsequent non-invasive detection of biological compounds
US5752512A (en) * 1995-05-10 1998-05-19 Massachusetts Institute Of Technology Apparatus and method for non-invasive blood analyte measurement
US5817031A (en) * 1994-12-07 1998-10-06 Omron Corporation Impedance measuring device and a health management device using the same
US5830140A (en) * 1994-11-23 1998-11-03 Quintsysteme Fur Holopathische Medizin Ges.M.B.H. Apparatus and method for registering substance-specific and organism-specific energetic information
US5830139A (en) * 1996-09-04 1998-11-03 Abreu; Marcio M. Tonometer system for measuring intraocular pressure by applanation and/or indentation
US5890489A (en) * 1996-04-23 1999-04-06 Dermal Therapy (Barbados) Inc. Method for non-invasive determination of glucose in body fluids
US5894939A (en) * 1996-10-09 1999-04-20 Frankel Industries, Inc. System for sorting post-consumer plastic containers for recycling
US6016445A (en) * 1996-04-16 2000-01-18 Cardiotronics Method and apparatus for electrode and transthoracic impedance estimation
US6044285A (en) * 1997-11-12 2000-03-28 Lightouch Medical, Inc. Method for non-invasive measurement of an analyte
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6246893B1 (en) * 1997-06-12 2001-06-12 Tecmed Incorporated Method and device for glucose concentration measurement with special attention to blood glucose determinations
US6261236B1 (en) * 1998-10-26 2001-07-17 Valentin Grimblatov Bioresonance feedback method and apparatus
US6266774B1 (en) * 1998-12-08 2001-07-24 Mcafee.Com Corporation Method and system for securing, managing or optimizing a personal computer
US6280381B1 (en) * 1999-07-22 2001-08-28 Instrumentation Metrics, Inc. Intelligent system for noninvasive blood analyte prediction
US6295468B1 (en) * 1999-03-13 2001-09-25 Bruno M. Hess Apparatus for measuring bioelectrical parameters
US6400983B1 (en) * 1999-08-09 2002-06-04 Biospace Co. Ltd. Apparatus for analyzing body composition using novel hand electrodes and method thereof
US6456865B2 (en) * 1995-06-08 2002-09-24 Ilan Zadik Samson Non-invasive medical probe
US20020138099A1 (en) * 2001-03-23 2002-09-26 Markin Jury Vladimirovich Method of and device for treating infections in living organism
US20030009111A1 (en) * 2001-06-13 2003-01-09 Cory Philip C. Non-invasive method and apparatus for tissue detection
US6517482B1 (en) * 1996-04-23 2003-02-11 Dermal Therapy (Barbados) Inc. Method and apparatus for non-invasive determination of glucose in body fluids
US6522903B1 (en) * 2000-10-19 2003-02-18 Medoptix, Inc. Glucose measurement utilizing non-invasive assessment methods
US20030045809A1 (en) * 2000-02-03 2003-03-06 Alexander Kanevsky Non-invasive method for disease diagnosis
US6544193B2 (en) * 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US6558320B1 (en) * 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6565509B1 (en) * 1998-04-30 2003-05-20 Therasense, Inc. Analyte monitoring device and methods of use
US6594521B2 (en) * 1999-12-17 2003-07-15 Electrical Geodesics, Inc. Method for localizing electrical activity in the body
US6599253B1 (en) * 2001-06-25 2003-07-29 Oak Crest Institute Of Science Non-invasive, miniature, breath monitoring apparatus
US6631282B2 (en) * 2001-08-09 2003-10-07 Optiscan Biomedical Corporation Device for isolating regions of living tissue
US20030220581A1 (en) * 2002-03-26 2003-11-27 Stig Ollmar Non-invasive in vivo determination of body fluid parameter
US6702743B2 (en) * 2000-05-26 2004-03-09 Inta-Medics, Ltd. Ultrasound apparatus and method for tissue resonance analysis
US6760617B2 (en) * 1999-06-22 2004-07-06 The University Of Queensland Method and device for measuring tissue oedema
US20040133081A1 (en) * 2002-10-09 2004-07-08 Eric Teller Method and apparatus for auto journaling of continuous or discrete body states utilizing physiological and/or contextual parameters
US20040133121A1 (en) * 2001-03-01 2004-07-08 Tamiko Ohkura Method and apparatus for analyzing organism reaction waveform information, and diagnosing apparatus
US6841389B2 (en) * 2001-02-05 2005-01-11 Glucosens, Inc. Method of determining concentration of glucose in blood
US6865407B2 (en) * 2002-07-11 2005-03-08 Optical Sensors, Inc. Calibration technique for non-invasive medical devices
US6866675B2 (en) * 2001-01-22 2005-03-15 Roche Diagnostics Operations, Inc. Lancet device having capillary action
US6954662B2 (en) * 2003-08-19 2005-10-11 A.D. Integrity Applications, Ltd. Method of monitoring glucose level
US20050238693A1 (en) * 2002-05-20 2005-10-27 Chemstop Pty Ltd. Process for the preparation and activation of susbstances and a means of producing same
US6990422B2 (en) * 1996-03-27 2006-01-24 World Energy Labs (2), Inc. Method of analyzing the time-varying electrical response of a stimulated target substance
US6996428B2 (en) * 2001-08-24 2006-02-07 Gen3 Partners, Inc. Biological signal sensor and device for recording biological signals incorporating the said sensor
US7016021B2 (en) * 2002-06-19 2006-03-21 Omron Corporation Method for measuring concentration of component contained in bodily fluid and apparatus for measuring concentration of component contained in bodily fluid
US7016713B2 (en) * 1995-08-09 2006-03-21 Inlight Solutions, Inc. Non-invasive determination of direction and rate of change of an analyte
US7027848B2 (en) * 2002-04-04 2006-04-11 Inlight Solutions, Inc. Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte
US7039446B2 (en) * 2001-01-26 2006-05-02 Sensys Medical, Inc. Indirect measurement of tissue analytes through tissue properties
US7130680B2 (en) * 2003-05-02 2006-10-31 Tanita Corporation Body composition measurement apparatus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557271A (en) 1983-05-11 1985-12-10 Stoller Kenneth P Method and apparatus for detecting body illness, dysfunction, disease and/or pathology
US5846189A (en) * 1989-09-08 1998-12-08 Pincus; Steven M. System for quantifying asynchrony between signals
US5769793A (en) * 1989-09-08 1998-06-23 Steven M. Pincus System to determine a relative amount of patternness
US5562596A (en) * 1989-09-08 1996-10-08 Steven M. Pincus Method and apparatus for controlling the flow of a medium
WO1992015955A1 (en) * 1991-03-07 1992-09-17 Vital Signals, Inc. Signal processing apparatus and method
US5579782A (en) 1993-08-12 1996-12-03 Omron Corporation Device to provide data as a guide to health management
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US6424847B1 (en) * 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
EP1466554B1 (en) 1999-10-12 2008-01-09 Tanita Corporation Living body measuring apparatus
US6328694B1 (en) 2000-05-26 2001-12-11 Inta-Medics, Ltd Ultrasound apparatus and method for tissue resonance analysis
JPWO2003062214A1 (en) 2002-01-23 2005-05-19 杏林製薬株式会社 Novel stable crystals of benzylthiazolidinedione derivatives and their preparation
CN1925786A (en) * 2004-03-06 2007-03-07 卡里斯托医药有限公司 Methods and devices for non-invasively measuring quantitative information of substances in living organisms

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US455271A (en) * 1891-06-30 Shingles
US3316896A (en) * 1962-10-18 1967-05-02 Thomasset Auguste Louis Apparatus and methods for the measure of the electrical impedance of living organisms
US3608543A (en) * 1968-10-03 1971-09-28 Univ Carnegie Mellon Physiological impedance-measuring apparatus
US3971366A (en) * 1974-11-25 1976-07-27 Hiroshi Motoyama Apparatus and method for measuring the condition of the meridians and the corresponding internal organs of the living body
US4016870A (en) * 1975-10-14 1977-04-12 Chuck Lock Electronic acupuncture point finder
US4392933A (en) * 1978-10-31 1983-07-12 Matsushita Electric Industrial Co., Ltd. Electrochemical measuring apparatus comprising enzyme electrode
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
US4408617A (en) * 1980-01-21 1983-10-11 Deloffre Auguste Apparatus for detecting the acupuncture points on a patient and for applying electrical stimulating signals to the detected points
US4494552A (en) * 1980-08-08 1985-01-22 R2 Corporation Physiological monitoring electrode system
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4539640A (en) * 1982-01-12 1985-09-03 Tasc Ltd. Reconstruction system and methods for impedance imaging
US5197951A (en) * 1983-12-14 1993-03-30 Mahurkar Sakharam D Simple double lumen catheter
US4655225A (en) * 1985-04-18 1987-04-07 Kurabo Industries Ltd. Spectrophotometric method and apparatus for the non-invasive
US4690152A (en) * 1985-10-23 1987-09-01 American Mediscan, Inc. Apparatus for epithelial tissue impedance measurements
US4714080A (en) * 1986-10-06 1987-12-22 Nippon Colin Co., Ltd. Method and apparatus for noninvasive monitoring of arterial blood oxygen saturation
US5163439A (en) * 1986-11-05 1992-11-17 Dardik Irving I Rhythmic biofeedback technique
US4897162A (en) * 1986-11-14 1990-01-30 The Cleveland Clinic Foundation Pulse voltammetry
US4911175A (en) * 1987-09-17 1990-03-27 Diana Twyman Method for measuring total body cell mass and total extracellular mass by bioelectrical resistance and reactance
US4883953A (en) * 1987-11-17 1989-11-28 Kurashiki Boseki Kabushiki Kaisha Spectroscopic method and apparatus for measuring sugar concentrations
US4882492A (en) * 1988-01-19 1989-11-21 Biotronics Associates, Inc. Non-invasive near infrared measurement of blood analyte concentrations
US4947862A (en) * 1988-10-28 1990-08-14 Danninger Medical Technology, Inc. Body composition analyzer
US5028787A (en) * 1989-01-19 1991-07-02 Futrex, Inc. Non-invasive measurement of blood glucose
US5086229A (en) * 1989-01-19 1992-02-04 Futrex, Inc. Non-invasive measurement of blood glucose
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
US5368028A (en) * 1989-08-11 1994-11-29 Cb-Carmel Biotechnology Ltd. System for monitoring and controlling blood and tissue constituent levels
US5050612A (en) * 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5267152A (en) * 1989-10-28 1993-11-30 Yang Won S Non-invasive method and apparatus for measuring blood glucose concentration
US5036861A (en) * 1990-01-11 1991-08-06 Sembrowich Walter L Method and apparatus for non-invasively monitoring plasma glucose levels
US5070874A (en) * 1990-01-30 1991-12-10 Biocontrol Technology, Inc. Non-invasive determination of glucose concentration in body of patients
US5222496A (en) * 1990-02-02 1993-06-29 Angiomedics Ii, Inc. Infrared glucose sensor
US5222495A (en) * 1990-02-02 1993-06-29 Angiomedics Ii, Inc. Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths
US5115133A (en) * 1990-04-19 1992-05-19 Inomet, Inc. Testing of body fluid constituents through measuring light reflected from tympanic membrane
US5146091A (en) * 1990-04-19 1992-09-08 Inomet, Inc. Body fluid constituent measurement utilizing an interference pattern
US5077476A (en) * 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
US5170199A (en) * 1990-07-09 1992-12-08 Fuji Photo Film Co., Ltd. Lens-fitted photographic film unit
US5131401A (en) * 1990-09-10 1992-07-21 Axon Medical Inc. Method and apparatus for monitoring neuromuscular blockage
US5063937A (en) * 1990-09-12 1991-11-12 Wright State University Multiple frequency bio-impedance measurement system
US5322063A (en) * 1991-10-04 1994-06-21 Eli Lilly And Company Hydrophilic polyurethane membranes for electrochemical glucose sensors
US5372141A (en) * 1992-07-01 1994-12-13 Body Composition Analyzers, Inc. Body composition analyzer
US5433197A (en) * 1992-09-04 1995-07-18 Stark; Edward W. Non-invasive glucose measurement method and apparatus
US5360004A (en) * 1992-12-09 1994-11-01 Diasense, Inc. Non-invasive determination of analyte concentration using non-continuous radiation
US5379764A (en) * 1992-12-09 1995-01-10 Diasense, Inc. Non-invasive determination of analyte concentration in body of mammals
US5339827A (en) * 1993-02-11 1994-08-23 Intech Scientific, Inc. Acupuncture system and method
US5568049A (en) * 1993-10-22 1996-10-22 The United States Of America As Represented By The Secretary Of The Navy Fiber optic faraday flux transformer sensor and system
US5590650A (en) * 1994-11-16 1997-01-07 Raven, Inc. Non-invasive medical monitor system
US5830140A (en) * 1994-11-23 1998-11-03 Quintsysteme Fur Holopathische Medizin Ges.M.B.H. Apparatus and method for registering substance-specific and organism-specific energetic information
US5817031A (en) * 1994-12-07 1998-10-06 Omron Corporation Impedance measuring device and a health management device using the same
US5752512A (en) * 1995-05-10 1998-05-19 Massachusetts Institute Of Technology Apparatus and method for non-invasive blood analyte measurement
US6456865B2 (en) * 1995-06-08 2002-09-24 Ilan Zadik Samson Non-invasive medical probe
US5720296A (en) * 1995-06-24 1998-02-24 Cha; Ki Chul Apparatus and method for analyzing body composition based on bioelectrical impedance analysis
US7016713B2 (en) * 1995-08-09 2006-03-21 Inlight Solutions, Inc. Non-invasive determination of direction and rate of change of an analyte
US5725480A (en) * 1996-03-06 1998-03-10 Abbott Laboratories Non-invasive calibration and categorization of individuals for subsequent non-invasive detection of biological compounds
US6990422B2 (en) * 1996-03-27 2006-01-24 World Energy Labs (2), Inc. Method of analyzing the time-varying electrical response of a stimulated target substance
US6016445A (en) * 1996-04-16 2000-01-18 Cardiotronics Method and apparatus for electrode and transthoracic impedance estimation
US5890489A (en) * 1996-04-23 1999-04-06 Dermal Therapy (Barbados) Inc. Method for non-invasive determination of glucose in body fluids
US6517482B1 (en) * 1996-04-23 2003-02-11 Dermal Therapy (Barbados) Inc. Method and apparatus for non-invasive determination of glucose in body fluids
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US7041063B2 (en) * 1996-09-04 2006-05-09 Marcio Marc Abreu Noninvasive measurement of chemical substances
US6544193B2 (en) * 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US6312393B1 (en) * 1996-09-04 2001-11-06 Marcio Marc A. M. Abreu Contact device for placement in direct apposition to the conjunctive of the eye
US5830139A (en) * 1996-09-04 1998-11-03 Abreu; Marcio M. Tonometer system for measuring intraocular pressure by applanation and/or indentation
US5894939A (en) * 1996-10-09 1999-04-20 Frankel Industries, Inc. System for sorting post-consumer plastic containers for recycling
US6999808B2 (en) * 1997-06-12 2006-02-14 Alan J. Leszinske Method and device for glucose concentration measurement with special attention to blood glucose determinations
US6246893B1 (en) * 1997-06-12 2001-06-12 Tecmed Incorporated Method and device for glucose concentration measurement with special attention to blood glucose determinations
US6044285A (en) * 1997-11-12 2000-03-28 Lightouch Medical, Inc. Method for non-invasive measurement of an analyte
US6377828B1 (en) * 1997-11-12 2002-04-23 Lightouch Medical, Inc. Method for non-invasive measurement of an analyte
US6565509B1 (en) * 1998-04-30 2003-05-20 Therasense, Inc. Analyte monitoring device and methods of use
US6261236B1 (en) * 1998-10-26 2001-07-17 Valentin Grimblatov Bioresonance feedback method and apparatus
US6266774B1 (en) * 1998-12-08 2001-07-24 Mcafee.Com Corporation Method and system for securing, managing or optimizing a personal computer
US6295468B1 (en) * 1999-03-13 2001-09-25 Bruno M. Hess Apparatus for measuring bioelectrical parameters
US6760617B2 (en) * 1999-06-22 2004-07-06 The University Of Queensland Method and device for measuring tissue oedema
US6280381B1 (en) * 1999-07-22 2001-08-28 Instrumentation Metrics, Inc. Intelligent system for noninvasive blood analyte prediction
US6400983B1 (en) * 1999-08-09 2002-06-04 Biospace Co. Ltd. Apparatus for analyzing body composition using novel hand electrodes and method thereof
US6594521B2 (en) * 1999-12-17 2003-07-15 Electrical Geodesics, Inc. Method for localizing electrical activity in the body
US6558320B1 (en) * 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US20030045809A1 (en) * 2000-02-03 2003-03-06 Alexander Kanevsky Non-invasive method for disease diagnosis
US20050197592A1 (en) * 2000-02-03 2005-09-08 Alexander Kanevsky Non-invasive method for disease diagnosis
US6702743B2 (en) * 2000-05-26 2004-03-09 Inta-Medics, Ltd. Ultrasound apparatus and method for tissue resonance analysis
US6522903B1 (en) * 2000-10-19 2003-02-18 Medoptix, Inc. Glucose measurement utilizing non-invasive assessment methods
US7039447B2 (en) * 2000-10-19 2006-05-02 Vivomedical, Inc. Glucose measurement utilizing non-invasive assessment methods
US6866675B2 (en) * 2001-01-22 2005-03-15 Roche Diagnostics Operations, Inc. Lancet device having capillary action
US7039446B2 (en) * 2001-01-26 2006-05-02 Sensys Medical, Inc. Indirect measurement of tissue analytes through tissue properties
US6841389B2 (en) * 2001-02-05 2005-01-11 Glucosens, Inc. Method of determining concentration of glucose in blood
US20040133121A1 (en) * 2001-03-01 2004-07-08 Tamiko Ohkura Method and apparatus for analyzing organism reaction waveform information, and diagnosing apparatus
US20020138099A1 (en) * 2001-03-23 2002-09-26 Markin Jury Vladimirovich Method of and device for treating infections in living organism
US20030009111A1 (en) * 2001-06-13 2003-01-09 Cory Philip C. Non-invasive method and apparatus for tissue detection
US6599253B1 (en) * 2001-06-25 2003-07-29 Oak Crest Institute Of Science Non-invasive, miniature, breath monitoring apparatus
US6631282B2 (en) * 2001-08-09 2003-10-07 Optiscan Biomedical Corporation Device for isolating regions of living tissue
US6996428B2 (en) * 2001-08-24 2006-02-07 Gen3 Partners, Inc. Biological signal sensor and device for recording biological signals incorporating the said sensor
US7050847B2 (en) * 2002-03-26 2006-05-23 Stig Ollmar Non-invasive in vivo determination of body fluid parameter
US20030220581A1 (en) * 2002-03-26 2003-11-27 Stig Ollmar Non-invasive in vivo determination of body fluid parameter
US7027848B2 (en) * 2002-04-04 2006-04-11 Inlight Solutions, Inc. Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte
US20050238693A1 (en) * 2002-05-20 2005-10-27 Chemstop Pty Ltd. Process for the preparation and activation of susbstances and a means of producing same
US7016021B2 (en) * 2002-06-19 2006-03-21 Omron Corporation Method for measuring concentration of component contained in bodily fluid and apparatus for measuring concentration of component contained in bodily fluid
US6865407B2 (en) * 2002-07-11 2005-03-08 Optical Sensors, Inc. Calibration technique for non-invasive medical devices
US20040133081A1 (en) * 2002-10-09 2004-07-08 Eric Teller Method and apparatus for auto journaling of continuous or discrete body states utilizing physiological and/or contextual parameters
US7130680B2 (en) * 2003-05-02 2006-10-31 Tanita Corporation Body composition measurement apparatus
US6954662B2 (en) * 2003-08-19 2005-10-11 A.D. Integrity Applications, Ltd. Method of monitoring glucose level

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8781565B2 (en) 2011-10-04 2014-07-15 Qualcomm Incorporated Dynamically configurable biopotential electrode array to collect physiological data
WO2013177451A1 (en) * 2012-05-25 2013-11-28 Qualcomm Incorporated Methods and devices for acquiring electrodermal activity
US9378655B2 (en) 2012-12-03 2016-06-28 Qualcomm Incorporated Associating user emotion with electronic media

Also Published As

Publication number Publication date
WO2005086725A3 (en) 2006-08-03
US7395104B2 (en) 2008-07-01
US20070156040A1 (en) 2007-07-05
WO2005086725A2 (en) 2005-09-22
JP2007527750A (en) 2007-10-04
EA200601463A1 (en) 2007-02-27
KR20060129507A (en) 2006-12-15
US20050197555A1 (en) 2005-09-08
CA2558239A1 (en) 2005-09-22
TW200535416A (en) 2005-11-01
AU2005220794A1 (en) 2005-09-22
IL177889A0 (en) 2006-12-31
EP1722681A2 (en) 2006-11-22
EP1722681A4 (en) 2010-03-03
CN1925786A (en) 2007-03-07

Similar Documents

Publication Publication Date Title
US7395104B2 (en) Methods and devices for non-invasively measuring quantitative information of substances in living organisms
CN106419891B (en) Apparatus and method for automated measurement of sural nerve conduction velocity and amplitude
KR101239340B1 (en) Portable pulse measuring device
US20040087838A1 (en) Meridian linking diagnostic and treatment system and method for treatment of manifested and latent maladies using the same
JP2010518952A (en) Electrophysiological analysis system
AU2002312721B2 (en) Method and device for detecting functional and metabolic data of a living organism
Cheggoju Development of Non-Invasive Glucose Sensor
CN101547637B (en) Detection pain/ awakening integral value
Critcher et al. Localized bioimpedance measurements with the max3000x integrated circuit: Characterization and demonstration
US10004445B2 (en) Apparatus and method for stimulator on-skin short detection
CN105395205A (en) Electrode non-invasive glucometer
Yang et al. A design of bioimpedance spectrometer for early detection of pressure ulcer
EP1839574A1 (en) Human organism examination band and human organism examination circuit
MXPA06010171A (en) Methods and devices for non-invasively measuring quantitative information of substances in living organisms
CN114786581A (en) Biological information measuring device
RU2303392C1 (en) Method of estimation of degree of influence of electromagnet fields onto human organism
KR101683038B1 (en) Oriental Medical Treatment System Based on Mobile Phone
CN104983428B (en) The blood glucose monitoring system of non-invasive
US11298055B2 (en) In vivo, noninvasive, bioelectromagnetic glucose sensor system and method
KR20200024759A (en) Information providing method, information processing system, information terminal, and information processing method
TWI259072B (en) Integrated apparatus for measuring physiological parameters
US20130261420A1 (en) System and method for non-invasive diagnostic of mammals
RU2107487C1 (en) Method and device for performing electroacupuncture diagnosis procedure taking into account mechanical and electric properties of acupuncture points
RU151023U1 (en) DEVICE FOR HEALTH CONTROL
JP2023503002A (en) Method and apparatus for ensuring that mammals are free of pain

Legal Events

Date Code Title Description
AS Assignment

Owner name: CALISTO MEDICAL, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOURADIAN, VAHRAM;ARMENAKYAN, VALERI;MALKIN, MAKSIM;AND OTHERS;REEL/FRAME:019120/0322;SIGNING DATES FROM 20050304 TO 20050305

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION